Benzodiazepines impair smooth pursuit eye movements

Area of Science:

• Pharmacology
• Neuroscience
• Ophthalmology

Background:

• Benzodiazepines are widely prescribed psychoactive drugs with known central nervous system effects.
• Oculomotor performance, specifically smooth pursuit eye movements, can be sensitive to neurological and pharmacological alterations.
• Understanding the quantitative relationship between benzodiazepine serum concentration and objective measures of cognitive or motor function is crucial.

Purpose of the Study:

• To investigate the effects of diazepam and temazepam on smooth pursuit eye movement (SPEM) velocity in healthy volunteers.
• To determine the correlation between serum benzodiazepine concentrations and the observed changes in oculomotor performance.
• To establish a dose-effect relationship for these benzodiazepines on a specific objective performance measure.

Main Methods:

• A double-blind, randomized, placebo-controlled study involving five healthy male volunteers.
• Administration of single oral doses: 10 mg diazepam, 20 mg temazepam, and placebo.
• Measurement of SPEM velocity and serum benzodiazepine concentrations at multiple time points post-administration (0.5-12 hours).

Main Results:

• A significant decrease in SPEM velocity compared to placebo was observed between 0.5-2 hours after temazepam and 1-2 hours after diazepam.
• SPEM velocity showed a log-linear correlation with serum concentrations of both temazepam and diazepam.
• The findings indicate a direct relationship between the amount of benzodiazepine in the bloodstream and its impact on eye movement control.

Conclusions:

• Diazepam and temazepam significantly impair smooth pursuit eye movement velocity in a time- and concentration-dependent manner.
• Serum benzodiazepine concentration is a reliable predictor of oculomotor performance deficits.
• This study provides objective evidence linking benzodiazepine levels to measurable effects on motor control, specifically eye movements.